The Company announced its fourth quarter and full year 2017 financial results.
The Company plans on attending the Cowen Health Care Conference on Wednesday, March 14 at 10:40 a.m. ET in Boston and the Barclays Global Healthcare Conference on Thursday, March 15 in Miami.
The Company met with several hundred veterinarians and veterinary staff at their IVECCS 2014 exhibit booth, at an exclusive Aratana Therapeutics reception and during an early morning breakfast to inform and educate the veterinary community on the novel therapeutics they are bringing to veterinary medicine.
The Company announced positive results from its pilot field study of AT-003 for managing post-operative pain in cats and dogs following surgery.
The Company announced that it will present at the Morgan Stanley Global Healthcare Conference, to be held September 8-10, 2014, at the Grand Hyatt in New York City.
The Company announced its second quarter 2014 results and plans to host a conference call August 12, 2014 at 8:30 a.m. ET.
The Company will host a conference call and live audio webcast on August 12, 201, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2014.
The Company today announced that it has appointed Irvine O. Hockaday, Jr. to its Board of Directors where he will also serve on the Nominating and Corporate Governance Committee.
Start-Ups Work on Biotech Drugs for Pets, by Andrew Pollack, was a feature article in The New York Times online August 2, 2014.
The Company announced that it has filed for a product license from the United States Department of Agriculture (USDA) for AT-014, a novel her2/neu-directed cancer immunotherapy licensed exclusively from Advaxis, Inc. (NASDAQ: ADXS) for the treatment of canine osteosarcoma and other cancers.
Denali, a therapy dog, inspires patients in hospitals, but is also an inspiration himself.
The Company announced the appointment of former Cephalon, Inc., executive Robert P. Roche, Jr. to its Board of Directors.
The Company will participate in two upcoming investor conferences, including the JMP Securities Healthcare Conference and Guggenheim Animal Health Day.
The Company announced that it is currently enrolling patients in two nationwide clinical trials to evaluate its monoclonal antibody for canine T-cell lymphoma, AT-005, which is conditionally licensed by the USDA to aid in the treatment of dogs with lymphoma.
Attendees at ACVIM Forum learned about the Aratana philosophy and got a preview to some of the exciting, innovative products that are in the Aratana pipeline for development.
The Compan announced it has entered into an exclusive license agreement with Vet-Stem, Inc., for its novel, allogeneic stem cell therapy technology.
The Company announced findings from the company’s ongoing safety and clinical programs, which were presented at the 2014 American College of Veterinary Internal Medicine (AVCIM) Forum.
Aratana is proud to call the Kansas City our home. Known as America’s Animal Health Corridor, Kansas City is the global leader for animal health and nutrition research, innovation and production.